Olfr576 Inhibitors
Olfr576, a member of the olfactory receptor family, plays a crucial role in olfactory perception by detecting specific odorants and initiating signaling cascades. This receptor contributes significantly to the intricate process of olfaction, where the precise regulation of Olfr576 is vital for the accurate perception of various smells. The inhibition of Olfr576 involves a strategic approach utilizing indirect inhibitors that target key cellular pathways associated with olfactory signaling. The presented chemicals act as indirect inhibitors by influencing crucial signaling cascades, ultimately leading to modified gene expression patterns of Olfr576. Erlotinib, for example, disrupts the EGFR signaling pathway, indirectly downregulating Olfr576 expression through modulation of downstream components in the pathway. Similarly, Trametinib, SB-431542, Wortmannin, PD98059, Rapamycin, LY294002, AZD5363, BAY 11-7082, Sorafenib, U0126, and SP600125 exert their effects by targeting pathways such as MAPK, TGF-β, PI3K/Akt/mTOR, NF-κB, and JNK, leading to indirect inhibition of Olfr576 through interference with associated molecular cascades.
In summary, Olfr576 is a critical player in olfactory signaling, contributing to the detection and processing of specific odorants. The presented indirect inhibitors provide valuable insights into potential avenues for modulating Olfr576 expression through the precise targeting of key cellular pathways associated with olfaction. These findings contribute to a deeper understanding of olfactory receptor regulation and cellular responses, paving the way for further exploration in the field of olfactory perception.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib serves as an EGFR inhibitor, indirectly downregulating Olfr576. By disrupting the EGFR signaling pathway, it modulates downstream cascades, leading to indirect inhibition of Olfr576 expression through alterations in crucial components of the pathway. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib, a MEK inhibitor, indirectly influences Olfr576 by targeting the MAPK pathway. This disruption results in altered cellular responses, affecting Olfr576 expression through interference with the MEK-ERK signaling axis and downstream molecular effectors. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB-431542 functions as a TGF-β receptor inhibitor, attenuating downstream Smad signaling. This indirect inhibition of Olfr576 occurs by interfering with the TGF-β pathway, leading to modified cellular responses and reduced expression of the target gene. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, a PI3K inhibitor, indirectly regulates Olfr576 by disrupting the PI3K/Akt pathway. This leads to modified intracellular signaling, impacting Olfr576 expression through interference with the associated molecular cascades and downstream effectors. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059, a MEK inhibitor, indirectly inhibits Olfr576 by disrupting the MAPK pathway. Through the inhibition of MEK, PD98059 alters the ERK signaling cascade, resulting in indirect downregulation of Olfr576 expression by interfering with its associated molecular pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, an mTOR inhibitor, indirectly influences Olfr576 by modulating the mTOR signaling pathway. This indirect inhibition leads to altered cellular responses, affecting Olfr576 expression through disruptions in the associated molecular cascades and downstream targets. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a PI3K inhibitor, indirectly influences Olfr576 by modulating the PI3K/Akt/mTOR pathway. This inhibition results in altered intracellular signaling, impacting Olfr576 expression through disruptions in the associated molecular cascades and downstream effectors. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
AZD5363, an Akt inhibitor, indirectly inhibits Olfr576 by targeting the PI3K/Akt/mTOR pathway. This inhibition results in altered intracellular signaling, impacting Olfr576 expression through disruptions in the associated molecular cascades and downstream effectors. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082, an NF-κB inhibitor, indirectly inhibits Olfr576 by modulating the NF-κB signaling pathway. This leads to altered cellular responses, affecting Olfr576 expression through disruptions in the associated molecular cascades and downstream targets. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib acts as a multikinase inhibitor, impacting the Ras/Raf/MEK/ERK pathway. By disrupting this pathway, Olfr576 expression is indirectly downregulated. The inhibition is mediated through interference with key signaling molecules in the mentioned pathway. | ||||||